GC Biopharma Corp. (KRX:006280)
South Korea
· Delayed Price · Currency is KRW 144,200
-7,900 (-5.19%)
At close: Mar 9, 2026
GC Biopharma Revenue
GC Biopharma had revenue of 609.49B KRW in the quarter ending September 30, 2025, with 31.11% growth. This brings the company's revenue in the last twelve months to 1.93T, up 17.66% year-over-year. In the year 2024, GC Biopharma had annual revenue of 1.68T with 3.27% growth.
Revenue (ttm)
1,934.38B
Revenue Growth
+17.66%
P/S Ratio
0.85
Revenue / Employee
947.30M
Employees
2,042
Market Cap
1,645.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,679.89B | 53.25B | 3.27% |
| Dec 31, 2023 | 1,626.64B | -84.67B | -4.95% |
| Dec 31, 2022 | 1,711.31B | 173.49B | 11.28% |
| Dec 31, 2021 | 1,537.83B | 33.71B | 2.24% |
| Dec 31, 2020 | 1,504.12B | 147.00B | 10.83% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Daewoong Pharmaceutical | 1,541.65B |
| Chong Kun Dang Pharmaceutical | 1,680.99B |
| Ildong Pharmaceutical | 575.66B |
| Daewoong | 2,055.93B |
| Celltrion Pharm | 274.73B |
| Hanall Biopharma | 154.05B |
| DongKook Pharmaceutical | 894.93B |
| Boryung | 1,028.99B |
GC Biopharma News
- 4 months ago - MedGenome Makes a Majority Investment in Leading Gujarat-Based Diagnostics Chain Green Cross to Expand Genomics Offerings Across India - Business Upturn